Evidence map›Paper›PMID 28490811›Full record

ArticleLeukemia2017

High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients.

J Pan, J F Yang, B P Deng, X J Zhao, X Zhang, Y H Lin, Y N Wu, Z L Deng, Y L Zhang, S H Liu and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Leukemia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 141 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
141citing papers in PubMed, 6 pooled it
10.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

141 citing papers in PubMed, 6 syntheses or guidelines pooled it, 232 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Ruxolitinib mitigates steroid-refractory CRS during CAR T therapy.Journal of cellular and molecular medicine · 2021
    Trial
  11. Trial
  12. Trial
  13. Trial
  14. Article
  15. Review
  16. Review
  17. Observational
  18. Impact ofFrontiers in immunology · 2026
    Article
  19. Review
  20. Article

81 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

J PanDepartment of Hematology, Hebei Yanda Lu Daopei Hospital, Yanjiao Economic and Technological Development Zone, Langfang, China.
J F YangDepartment of Hematology, Hebei Yanda Lu Daopei Hospital, Yanjiao Economic and Technological Development Zone, Langfang, China.
B P DengDepartment of Immunotherapy, Hebei Yanda Lu Daopei Hospital, Langfang, China.
X J ZhaoClinical Translational Research Center, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
X ZhangDepartment of Hematology, Hebei Yanda Lu Daopei Hospital, Yanjiao Economic and Technological Development Zone, Langfang, China.
Y H LinDepartment of Hematology, Hebei Yanda Lu Daopei Hospital, Yanjiao Economic and Technological Development Zone, Langfang, China.
Y N WuDepartment of Immunotherapy, Hebei Yanda Lu Daopei Hospital, Langfang, China.
Z L DengDepartment of Immunotherapy, Hebei Yanda Lu Daopei Hospital, Langfang, China.
Y L ZhangClinical Translational Research Center, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
S H LiuClinical Translational Research Center, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
T WuDepartment of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, China.
P H LuDepartment of Hematology, Hebei Yanda Lu Daopei Hospital, Yanjiao Economic and Technological Development Zone, Langfang, China.
D P LuDepartment of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, China.
A H ChangClinical Translational Research Center, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
C R TongDepartment of Hematology, Hebei Yanda Lu Daopei Hospital, Yanjiao Economic and Technological Development Zone, Langfang, China.
Tongji University · CNShanghai Pulmonary Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Refractory or relapsed B lymphoblastic leukemia (B-ALL) patients have a dismal outcome with current therapy. We treated 42 primary refractory/hematological relapsed (R/R) and 9 refractory minimal residual disease by flow cytometry (FCM-MRD

Indexed as

Immunotherapy, AdoptiveAdolescentAdultAnimalsAntigens, CD19Antineoplastic Combined Chemotherapy ProtocolsChildChild, PreschoolCohort StudiesCombined Modality TherapyDisease Models, AnimalDrug Resistance, NeoplasmFemaleHematopoietic Stem Cell TransplantationHeterograftsHumansAntigens, CD19

Identifiers

PMID28490811
OpenAlexW2613659662

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.